#United Kingdom #Cancer Research #Glasgow #Stellaromics #Pyxa Platform

Stellaromics Launches Pyxa Platform in Europe

Stellaromics, a leading innovator in the field of 3D spatial biology, has reached a monumental milestone with the inaugural deployment of its Pyxa platform in Europe. This groundbreaking achievement took place in collaboration with Dr. Nigel Jamieson and his esteemed team at the University of Glasgow, marking a significant advancement in the realm of oncology research.

A New Era in Cancer Research

On April 24, 2025, Stellaromics formally announced this deployment, establishing itself as a pivotal player in cancer research innovation. Dr. Jamieson, a distinguished physician-scientist and professor at the University of Glasgow, has become the first European user of the Pyxa platform as an early access partner. His research will specifically focus on leveraging Pyxa's advanced capabilities to delve into the complexities of tumor architecture along with the surrounding microenvironment, aiming to identify new cancer biomarkers that could greatly influence pharmaceutical development and potential clinical applications.

Dr. Jamieson’s lab not only serves as a research facility but also operates as a core platform for spatial biology, utilizing the comprehensive workflow offered by Pyxa. This technique encompasses everything from meticulous sample preparation and intricate 3D spatial sequencing to sophisticated data analysis, effectively generating high-resolution maps of tumor samples. Through enhanced visualization of tumors at sub-cellular resolution and comprehensive analysis of thick tissue sections integrated with multi-omic data, the team strives to uncover the intricate cellular interactions and disease mechanisms that underlie cancer, with unmatched precision.

Advancing Diagnostic and Therapeutic Applications

The introduction of the Pyxa platform signifies a transformative leap forward not only for Stellaromics but also for the entire realm of cancer diagnostics and therapeutics. Dr. Jamieson remarks, “Studying tumors in 3D gives us a much richer understanding of how cancer behaves in real tissues. The ability to analyze thicker sections and integrate multi-omic data opens up new avenues for discovering biomarkers and developing more tailored therapies.” This exciting new capability could shape the future of cancer treatment significantly, offering deeper insights into tumor biology.

Stellaromics’ CEO, Dr. Todd Dickinson, expressed enthusiasm about this partnership, stating, “Collaborating with Dr. Jamieson and the University of Glasgow for our first European site represents not just a geographic expansion, but also a chance to work alongside passionate researchers who are pushing the limits of cancer science.” He underscored the firm’s commitment to providing cutting-edge tools that aid in the fight against cancer, highlighting Pyxa’s considerable potential.

This collaboration is expected to be highlighted at the upcoming event titled the “Next-Generation Cancer Diagnostics Grand Challenge” scheduled for May 9 in London. This event will bring together leaders from the UK Department of Health, pharmaceutical companies, and researchers specializing in spatial biology, providing a platform for discussing advancements in cancer diagnostics and therapeutics.

Looking Ahead

Stellaromics plans to broaden its early access program with additional instruments set to ship in the summer of 2025, paving the way for more researchers to engage with this innovative platform.

Stellaromics, headquartered in Boston, Massachusetts, has committed itself to pioneering advancements in the understanding of complex biological systems through its innovative 3D spatial multi-omics solutions.

In summary, the launch of the Pyxa platform in Europe marks a significant development in cancer research, providing unprecedented insights and opportunities for the scientific community. As Stellaromics forges ahead, it continues to illuminate pathways for groundbreaking discoveries that aim to enhance human health globally.